Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ECVAM News & Views

ECVAM News & Views ATLA 34, 277–280, 2006 277 Endorsement of Alternative Methods ECVAM and the REACH Implementation Project 3.3 Endpoint to Animal Testing by the ECVAM Working Groups Scientific Advisory Committee at its 24th meeting The objective of REACH Implementation Project (RIP) 3.3 is to develop guidance for industry on how The ESAC endorsed the scientific validity of seven to fulfil the information requirements on the intrin- alternative methods at its 24th meeting held on sic properties of substances. This should, in particu- 20–21 March 2006 at ECVAM, Ispra, Italy. lar, give a better insight on how to use data derived from alternatives to animal methods, such as — Five human-cell based in vitro tests for the detec- (Q)SARs, chemical category approaches, and in vitro tion of pyrogens in drugs for injections (ECVAM tests, and on how information on exposure can be collaborated with DG Research in this success- taken into account. ECVAM staff are represented in fully completed international validation project). various endpoint working groups of RIP 3.3. The first Stakeholder Expert Group (SEG) meeting — The Colony Forming Unit-Granulocyte/Macro- was held on 9 March 2006, at ECVAM. The SEG is phage (CFU-GM) Assay for Predicting Acute coordinated by ECVAM and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Alternatives to Laboratory Animals SAGE

ECVAM News & Views

Alternatives to Laboratory Animals , Volume 34 (3): 4 – Jun 1, 2006
Download PDF
4 pages

Loading next page...
 
/lp/sage/ecvam-news-views-tfLJAgKvh0

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
SAGE
Copyright
© 2006 Fund for the Replacement of Animals in Medical Experiments
ISSN
0261-1929
eISSN
2632-3559
DOI
10.1177/026119290603400306
Publisher site
See Article on Publisher Site

Abstract

ATLA 34, 277–280, 2006 277 Endorsement of Alternative Methods ECVAM and the REACH Implementation Project 3.3 Endpoint to Animal Testing by the ECVAM Working Groups Scientific Advisory Committee at its 24th meeting The objective of REACH Implementation Project (RIP) 3.3 is to develop guidance for industry on how The ESAC endorsed the scientific validity of seven to fulfil the information requirements on the intrin- alternative methods at its 24th meeting held on sic properties of substances. This should, in particu- 20–21 March 2006 at ECVAM, Ispra, Italy. lar, give a better insight on how to use data derived from alternatives to animal methods, such as — Five human-cell based in vitro tests for the detec- (Q)SARs, chemical category approaches, and in vitro tion of pyrogens in drugs for injections (ECVAM tests, and on how information on exposure can be collaborated with DG Research in this success- taken into account. ECVAM staff are represented in fully completed international validation project). various endpoint working groups of RIP 3.3. The first Stakeholder Expert Group (SEG) meeting — The Colony Forming Unit-Granulocyte/Macro- was held on 9 March 2006, at ECVAM. The SEG is phage (CFU-GM) Assay for Predicting Acute coordinated by ECVAM and

Journal

Alternatives to Laboratory Animals – SAGE

Published: Jun 1, 2006

There are no references for this article.